5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target

Abstract

	•5hmC epigenetic markers derived from portal venous blood could accurately predict metachronous metastasis of colorectal cancer.
	•PDE4D was a key metastasis-driven target that promoted metachronous metastasis via the HIF-1α-CCN2 pathway.
	•The newly synthesised compound L11 could specifically inhibit PDE4D and abolish metachronous metastasis of colorectal cancer without obvious toxic side effects.

Keywords

5hmC-Seal / Colorectal cancer / Metachronous liver metastases / PDE4D

References

[1] SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7-34.

[2] DekkerE, TanisPJ, VleugelsJLA, Kasi PM, WallaceMB. Colorectal cancer. Lancet. 2019; 394: 1467-1480.

[3] Pita-FernándezS, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-PilladoT, Pértega-DíazS. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015; 26: 644-656.

[4] BonneyGK, ChewCA, LodgeP, et al. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The lancet Gastroenterology & hepatology. 2021; 6: 933-946.

[5] KemenyN. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010; 22: 364-373.

[6] Al BandarMH, KimNK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer (Review). Oncol Rep. 2017; 37: 2553-2564.

[7] TakahashiH, BerberE. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobil Surg Nutrition. 2020; 9: 49-58.

[8] ZhouH, LiuZ, WangY, et al. Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Targeted Therap. 2022; 7: 70.

[9] TangM, WangH, CaoY, ZengZ, ShanX, Wang L. Nomogram for predicting occurrence and prognosis of liver metastasis in colorectal cancer: a population-based study. Int J Colorect Dis. 2021; 36: 271-282.

[10] BillerLH, SchragD. Diagnosis and treatment of metastatic colorectal cancer: a review. Jama. 2021; 325: 669-685.

[11] LiC, SunYi-Di, YuG-Y, et al. integrated omics of metastatic colorectal cancer. Cancer Cell. 2020; 38: 734-747. e739.

[12] OliveiraRC, Alexandrino H, CiprianoMA, AlvesFC, Tralhão JG. Predicting liver metastases growth patterns: current status and future possibilities. Seminars in cancer biology. 2021; 71: 42-51.

[13] TsilimigrasDI, BrodtP, ClavienP-A, et al. Liver metastases. Nat Rev. 2021; 7: 27.

[14] NormannoN, Cervantes A, CiardielloF, De LucaA, PintoC. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat Rev. 2018; 70: 1-8.

[15] CannellaR, Tselikas L, DouaneF, et al. Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Rep. 2022; 4: 100484.

[16] SubbotinVM. Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets. Drug Discov Today. 2018; 23: 548-564.

[17] RiddioughGE, JalalQ, PeriniMV, Majeed AW. Liver regeneration and liver metastasis. Semin Cancer Biol. 2021; 71: 86-97.

[18] CatenacciDVT, Chapman CG, XuP, et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology. 2015; 149: 1794-1803. e1794.

[19] ChapmanCG, AyoubF, SweiE, et al. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers. Pancreatology. 2020; 20: 1747-1754.

[20] ZhangY, SuH, WangH, et al. Endoscopic ultrasound-guided acquisition of portal venous circulating tumor cells as a potential diagnostic and prognostic tool for pancreatic cancer. Cancer Manag Res. 2021; 13: 7649-7661.

[21] JiaoLR, Apostolopoulos C, JacobJ, et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol. 2009; 27: 6160-6165.

[22] ChenH-Yu, ZhangW-L, ZhangL, et al. 5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients. Clin Epigenetics. 2021; 13: 33.

[23] LiW, ZhangXu, LuX, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27: 1243-1257.

[24] SongC-X, YinS, MaLi, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017; 27: 1231-1242.

[25] CuiX-L, NieJi, KuJ, et al. A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation. Nat Commun. 2020; 11: 6161.

[26] CaiJ, ChenL, ZhangZ, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019; 68: 2195-2205.

[27] HeB, ZhangC, ZhangX, et al. Tissue-specific 5-hydroxymethylcytosine landscape of the human genome. Nat Commun. 2021; 12: 4249.

[28] GulerGD, NingY, KuC-J, et al. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA. Nat Commun. 2020; 11: 5270.

[29] ChenH-Yu, LiX-X, LiC, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free dna as early warning biomarkers for COVID-19 progression and myocardial injury. Front Cell Dev Biol. 2021; 9: 781267.

[30] TianX, SunB, ChenC, et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. Cell Res. 2019; 28: 597-600.

[31] YangY, ZengC, LuX, et al. 5-Hydroxymethylcytosines in circulating cell-free DNA reveal vascular complications of type 2 diabetes. Clin Chem. 2019; 65: 1414-1425.

[32] DongC, ChenJ, ZhengJ, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic and predictive biomarkers for coronary artery disease. Clin Epigenetics. 2020; 12: 17.

[33] BrancoMR, FiczG, ReikW. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev. 2011; 13: 7-13.

[34] QuailDF, JoyceJA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19: 1423-1437.

[35] CioroianuAI, StingaPI, SticlaruL, et al. Tumor microenvironment in diffuse large B-cell lymphoma: role and prognosis. Analyt Cell Pathol (Amsterdam). 2019; 2019: 8586354.

[36] Roma-RodriguesC, MendesR, BaptistaPV, Fernandes AR. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019; 20.

[37] ManiDR, KrugK, ZhangB, et al. Cancer proteogenomics: current impact and future prospects. Nat Rev. 2022; 22: 298-313.

[38] LinW-H, ChangYi-W, HongM-X, et al. STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis. Oncogene. 2021; 40: 791-805.

[39] LiuB, SunL, LiuQ, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015; 27: 370-381.

[40] ZhangJ, WangS, JiangB, et al. c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis. Nat Commun. 2017; 8: 13732.

[41] XuRX, Hassell AM, VanderwallD, et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (New York, NY). 2000; 288: 1822-1825.

[42] Pérez-TorresS, Miró X, PalaciosJM, CortésR, Puigdoménech P, MengodG. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat. 2000; 20: 349-374.

[43] LakicsV, KarranEH, BoessFG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010; 59: 367-374.

[44] ContrerasS, MilaraJ, MorcilloE, Cortijo J. Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences. Curr Pharmaceut Design. 2017; 23: 2073-2083.

[45] TranCM, FujitaN, HuangB-L, et al. Hypoxia-inducible factor (HIF)-1α and CCN2 form a regulatory circuit in hypoxic nucleus pulposus cells: CCN2 suppresses HIF-1α level and transcriptional activity. J Biol Chem. 2013; 288: 12654-12666.

[46] WuZ, ZhouC, YuanQ, Zhang D, XieJ, ZouS. CTGF facilitates cell-cell communication in chondrocytes via PI3K/Akt signalling pathway. Cell Prolifer. 2021; 54: e13001.

[47] HashiguchiS, TanakaT, ManoR, Kondo S, KodamaS. CCN2-induced lymphangiogenesis is mediated by the integrin αvβ5-ERK pathway and regulated by DUSP6. Sci Rep. 2022; 12: 926.

[48] YangY, TanY-X, ChenR-Y, Kang J. The latest review on the polyphenols and their bioactivities of Chinese Morus plants. J Asian Nat Prod Res. 2014; 16: 690-702.

[49] ChenS-Ke, ZhaoP, ShaoY-X, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2012; 22: 3261-3264.

[50] HuangY, LiuX, WuD, et al. The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochem Pharmacols. 2017; 130: 51-59.

[51] MeyerY, OlthofPB, GrünhagenDJ, et al. Treatment of metachronous colorectal cancer metastases in the Netherlands: a population-based study. Eur J Surg Oncol. 2022; 48: 1104-1109.

[52] ZviranA, Schulman RC, ShahM, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020; 26: 1114-1124.

[53] PantelK, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16: 398-406.

[54] IgnatiadisM, SledgeGW, JeffreySS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021; 18: 297-312.

[55] BachmanM, Uribe-Lewis S, YangX, WilliamsM, Murrell A, BalasubramanianS. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem. 2014; 6: 1049-1055.

[56] MooijmanD, DeySS, BoissetJ-C, Crosetto N, Van OudenaardenA. Single-cell 5hmC sequencing reveals chromosome-wide cell-to-cell variability and enables lineage reconstruction. Nat Biotechnol. 2016; 34: 852-856.

[57] LiuL, ToungJM, JassowiczAF, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018; 29: 1445-1453.

[58] ShenSYi, Singhania R, FehringerG, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018; 563: 579-583.

[59] ChapmanCG, WaxmanI. EUS-guided portal venous sampling of circulating tumor cells. Curr Gastroenterol Rep. 2019; 21: 68.

[60] YangX, BiX, LiuF, HuangJ, ZhangZ. predictive efficacy of circulating tumor cells in first drainage vein blood from patients with colorectal cancer liver metastasis. Cancer Investig. 2022: 1-10.

[61] EngstrandJ, Strömberg C, NilssonH, FreedmanJ, JonasE. Synchronous and metachronous liver metastases in patients with colorectal cancer-towards a clinically relevant definition. World J Surg Oncol. 2019; 17: 228.

[62] Van Den EyndenGG, Majeed AW, IllemannM, et al. The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 2013; 73: 2031-2043.

[63] LiW, GuoL, TangW, et al. Identification of DNA methylation biomarkers for risk of liver metastasis in early-stage colorectal cancer. Clin Epigenetics. 2021; 13: 126.

[64] HaoM, WangK, DingY, Li H, LiuY, DingL. Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. Euro J Med Res. 2022; 27: 130.

[65] XiaoC, ZhouM, YangX, et al. Accurate prediction of metachronous liver metastasis in Stage I-III colorectal cancer patients using deep learning with digital pathological images. Front Oncol. 2022; 12: 844067.

[66] TaghaviM, Trebeschi S, SimõesR, et al. Machine learning-based analysis of CT radiomics model for prediction of colorectal metachronous liver metastases. Abdominal Radiol (New York). 2021; 46: 249-256.

[67] LiY, GongJ, ShenX, et al. Assessment of primary colorectal cancer CT radiomics to predict metachronous liver metastasis. Front Oncol. 2022; 12: 861892.

[68] ArmaghanyT, et al. Genetic alterations in colorectal cancer. Gastrointestinal cancer Res. 2012; 5: 19-27.

[69] ZengX, WardSE, ZhouJ, Cheng ASL. Cheng, liver immune microenvironment and metastasis from colorectal cancer-pathogenesis and therapeutic perspectives. Cancers. 2021; 13.

[70] PretzschE, Bösch F, NeumannJ, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019; 2019: 7407190.

[71] ZaccoloM, ZerioA, LoboMJ, Garland C. Subcellular organization of the cAMP signaling pathway. Pharmacol Rev. 2021; 73: 278-309.

[72] ZhangF, ZhangL, QiY, XuH. Mitochondrial cAMP signaling. Cell Mol Life Sci. 2016; 73: 4577-4590.

[73] DuaP, GudeRP. Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation. Eur J Cancer. 2008; 44: 1587-1595.

[74] ZimmermanNP, RoyI, HauserAD, Wilson JM, WilliamsCL, DwinellMB. Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol Carcinog. 2015; 54: 203-215.

[75] JiangKe, YaoG, HuL, et al. MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling. Cell Death Dis. 2020; 11: 230.

[76] YangF, Tuxhorn JA, ResslerSJ, McalhanySJ, DangTD, RowleyDR. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005; 65: 8887-8895.

[77] DornhöferN, SpongS, BennewithK, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006; 66: 5816-5827.

[78] ShaW, LeaskA. CCN2 expression and localization in melanoma cells. J Cell Commun Signaling. 2011; 5: 219-226.

[79] UbinkI, Verhaar ER, KranenburgO, GoldschmedingR. A potential role for CCN2/CTGF in aggressive colorectal cancer. J Cell Commun Signal. 2016; 10: 223-227.

[80] LinB-R, ChangC-C, ChenRJ-C, et al. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer. Clin Cancer Res. 2011; 17: 3077-3088.

[81] GuoY, LiX, LinC, et al. MicroRNA 133b inhibits connective tissue growth factor in colorectal cancer and correlates with the clinical stage of the disease. Mol Med Rep. 2015; 11: 2805-2812.

[82] PierobonM, RamosC, WongS, et al. Enrichment of PI3K-AKT-mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. 2017; 23: 4919-4928.

[83] ZhangY, ChengH, LiW, WuH, YangY. Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. Int J Cancer. 2019; 145: 1068-1082.

[84] WenS, HouY, FuL, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling. Cancer Lett. 2019; 442: 320-332.

[85] XiangZ, LiJ, SongS, et al. A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis. J Exp Clin Cancer Res: CR. 2019; 38: 314.

[86] Garnock-JonesKP. Roflumilast: a review in COPD. Drugs. 2015; 75: 1645-1656.

[87] RabeKF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011; 163: 53-67.

[88] RabeKF, Bateman ED, O’donnellD, WitteS, Bredenbröker D, BethkeTD. Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005; 366: 563-571.

[89] SongC-X, Szulwach KE, FuYe, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011; 29: 68-72.

[90] SongC-X, YinS, MaLi, et al. 5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages. Cell Res. 2017; 27: 1231-1242.

[91] LangmeadB, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9: 357-359.

[92] LiH, Handsaker B, WysokerA, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics (Oxford, England). 2009; 25: 2078-2079.

[93] QuinlanAR. BEDTools: the Swiss-Army tool for genome feature analysis. Curr Protocol Bioinform. 2014; 47. 11.12.11-34.

[94] ENCODE Project Consortium, BirneyE, StamatoyannopoulosJA, et al, ENCODE ProjectConsortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007; 447: 799-816.

[95] SwamiA, et al. Scikit-learn: machine Learning in Python. J Mach Learning Res∖. 2013; 12: 2825-2830.

[96] YuG, WangLG, HeQY, et al. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics (Oxford, England). 2015; 31: 2382-2383.

[97] ZhouY, ZhouB, PacheL, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10: 1523.

[98] HuangY, LiuX, WuD, et al. The discovery, complex crystal structure, and recognition mechanism of a novel natural PDE4 inhibitor from Selaginella pulvinata. Biochem Pharmacol. 2017; 130: 51-59.

[99] HuangYi-Y, YuY-Fa, ZhangC, et al. Validation of Phosphodiesterase-10 as a novel target for pulmonary arterial hypertension via highly selective and subnanomolar inhibitors. J Med Chem. 2019; 62: 3707-3721.

[100] ZhangT, LaiZ, YuanS, et al. Discovery of evodiamine derivatives as highly selective PDE5 inhibitors targeting a unique allosteric pocket. J Med Chem. 2020; 63: 9828-9837.

[101] LiangJ, HuangYi-Y, ZhouQ, et al. Discovery and optimization of α-mangostin derivatives as novel PDE4 inhibitors for the treatment of vascular dementia. J Med Chem. 2020; 63: 3370-3380.

[102] AdamsPD, Afonine PV, BunkócziG, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. 2010; 66: 213-221.

[103] EmsleyP, CowtanK. Coot: model-building tools for molecular graphics. Acta crystallographica. 2004; 60: 2126-2132.

[104] DastidarSG, RayA, ShirumallaR, et al. Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology. 2009; 83: 275-286.

[105] NoseT, KondoM, ShimizuM, et al. Pharmacological profile of GPD-1116, an inhibitor of phosphodiesterase 4. Biol Pharmaceut Bull. 2016; 39: 689-698.

[106] Total synthesis of the 2-arylbenzo[b]furan-containing natural products from Artocarpus. Tetrahedr Lett. 2015; 56: 4383-4387.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.